Experience with the long-term use of interferons β in the treatment of relapsing-remitting multiple sclerosis. Case report

Abstract

Current approaches to treating multiple sclerosis aim at controlling disease activity. Despite the variety of agents that have proven their effectiveness and were introduced in practice in the last decade, the use of the interferon β group remains relevant. The article presents clinical cases of long-term use of interferons β in treating multiple sclerosis.